Eli Lilly and Resilience Unveil $750 Million Investment to Boost Production of Diabetes and Obesity Medications

Eli Lilly and biomanufacturer Resilience are investing $750 million to enhance the production of diabetes and obesity medications, specifically focusing on the KwikPen injectable device. This partnership will create around 400 jobs, with production expected to commence in 2027. Resilience, which recently relocated its headquarters to Blue Ash, Ohio, currently operates two facilities in the Cincinnati area. The expansion highlights Ohio’s growing role in biomanufacturing and aims to address the rising demand for high-demand treatments.